Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in @entity1 with refractory recurrent XXXX .

@entity1 @entity4562 @entity11730 @entity66 @entity5 @entity310 @entity2 @entity2533 @entity1820 @entity74 @entity379 @entity3646 @entity2220
UNASSIGNED: 2541 Background: Autologous @entity5 cells stimulated T lymphocytes (AuTL) were generated ex vivo from peripheral blood lymphocytes (PBL) over a two week co-culturing process and they may have potential for efficacy as a cellular immunotherapy (IT) in refractory @entity1820 @entity1 (pts). We investigated the feasibility of a combination of AuTL transfer and chemotherapy (ChT) with S1or @entity4562 (Iressa) conditioning regimen in order to take advantage by both the anticancer and lymphodepleted effects for reconstruction of antitumor immune followed by AuTL transfer as well as an adoptive IT. METHOD: 13 @entity1 were enrolled in a pilot clinical trial. The two administrations of AuTL were given prior to one ChT for one treatment cycle. The treatment was repeated at least three cycles with a one-week interval. The nonmyeloablative ChT regimen was based on standard dose of @entity11730 for pts with gastric (4 pts), colon (4 pts) or esophageal (3 pts) @entity5 and of @entity4562 for 2 pts with @entity2220 . AuTLs were administered 1x/2weeks using IV for @entity2 and direct injection or IA for @entity1820 . RESULTS: The median period of treatment was over 12.6 months and median survival time is 14.8 months. Adverse events related to both of the ChT and AuTL transfer were minimal. 4 of 13 pts achieved major @entity5 responses (2 CR: complete regression and 2 PR: partial regression). 3 pts had @entity74 ( @entity74 ). 6 pts had @entity66 ( @entity66 ) for over 90 days. PBLs were evaluated for cytokine production prior to treatment and after 3 treatments. After treatment, three of 4 CR/PR pts had increased @entity379 or @entity310 production. Two of 6 @entity66 pts had high @entity379 and @entity310 responses. @entity2533 and @entity3646 secretion increased simultaneously in 3/3 @entity74 pts. CONCLUSIONS: These results show that combination therapy of AuTL transfer and non-myeloablative ChT is a feasible option for pts with @entity5 . Using the synergistic mechanism of IT and ChT, a more stringent clinical evaluation of AuTL transfer combined with nonmyeloablative ChT should be performed for various @entity5 to improve the effect of this new approach. No significant financial relationships to disclose.
